Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) has provided an announcement.
Alligator Bioscience announced the acceptance of two abstracts for presentation at the Society for Immunotherapy of Cancer’s 40th Anniversary Annual Meeting. This recognition highlights the strength of Alligator’s pipeline, particularly their lead drug candidate mitazalimab, which is ready for Phase 3 development. The company’s innovative immunotherapies aim to provide significant benefits for cancer patients, reinforcing its position in the biotechnology industry.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company based in Lund, Sweden, specializing in the development of clinical-stage tumor-directed antibody drugs. The company’s focus is on the CD40 receptor, a validated immuno-oncology approach that enhances T cell priming and counteracts the immunosuppressive nature of the tumor microenvironment. Alligator Bioscience is listed on Nasdaq Stockholm under the ticker ATORX.
YTD Price Performance: -78.81%
Average Trading Volume: 506,539
Technical Sentiment Signal: Sell
Current Market Cap: SEK195.4M
See more insights into ATORX stock on TipRanks’ Stock Analysis page.